Covid-19: Russian vaccine efficacy is 91.6%, show phase III trial results
Elisabeth Mahase
Abstract
Covid-19: Russian vaccine efficacy is 91.6%, show phase III trial results Elisabeth MahaseThe covid-19 vaccine developed by the Gamaleya Research Institute, part of the Russian Ministry of Health, has an efficacy of 91.6%, according to interim results from a phase III trial. 1 The findings, published in the Lancet, showed that the two dose regime of the viral vector vaccine was generally well tolerated with no associated serious adverse events and similar efficacy in those aged over and under 60.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)InterimChristian ministryVaccine trialMedicineAdverse effectPhase (matter)2019-20 coronavirus outbreakVirologyClinical trialVaccine efficacySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Family medicineVaccinationInternal medicinePolitical scienceOutbreakDiseaseLawInfectious disease (medical specialty)ChemistryOrganic chemistrySARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies